Finally, although the significance of our findings is not certain given that the standard first-line treatment for ovarian cancer is a combination of platinum with a taxane, we think that our data could provide, if confirmed in a wider series, the rationale to ask for the immunohistochemical assessment of COX-2 status as predictor of response to treatment, only in cases triaged to platinum-based therapy (including platinum/anthracycline or platinum/alkylants combinations, which are still a valid option in selected patients). Here, PTGS2 is linked to ovarian carcinoma.